I don't think the ACCC will allow this transaction as it will result in CellCare having a 90% monopoly.
However if it does go ahead it looks to be a great deal for CTE:
- Cash backed valuation (including future earnouts)
- Clinical business for free (assuming cashflow positive)
My interest is with companies that are leveraged to clinical trial revenue as I've seen several microcaps increase this part of their business very quickly from a low base over the years.
I don't think the ACCC will allow this transaction as it will...
Add CTE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
85.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $39.04M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 630 | 80.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 85.0¢ | 39 | 1 |
View Market Depth
| Last trade - 10.02am 04/12/2024 (20 minute delay) ? |
| CTE (ASX) Chart |
Day chart unavailable
